Reviewing LENSAR (NASDAQ:LNSR) & CardioGenics (OTCMKTS:CGNH)

CardioGenics (OTCMKTS:CGNH) and LENSAR (NASDAQ:LNSR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Insider and Institutional Ownership

40.2% of LENSAR shares are owned by institutional investors. 41.4% of CardioGenics shares are owned by company insiders. Comparatively, 66.0% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

CardioGenics has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Valuation and Earnings

This table compares CardioGenics and LENSAR”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
LENSAR	$53.49 million	2.60	-$31.40 million	($4.39)	-2.66

CardioGenics has higher earnings, but lower revenue than LENSAR.

Analyst Ratings

This is a summary of recent ratings and recommmendations for CardioGenics and LENSAR, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
LENSAR	1	2	0	0	1.67

LENSAR has a consensus price target of $15.00, indicating a potential upside of 28.53%. Given LENSAR’s stronger consensus rating and higher possible upside, analysts plainly believe LENSAR is more favorable than CardioGenics.

Profitability

This table compares CardioGenics and LENSAR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
LENSAR	-87.12%	N/A	-73.64%

Summary

LENSAR beats CardioGenics on 5 of the 8 factors compared between the two stocks.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About LENSAR

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.